CELC Celcuity Inc

$CELC I learned my lesson from CORT. When a company is generating $750M off a single drug, buy the F OUT OF IT when it dumps during the wider market or a short term binary event $CORT now up 300% in just a year 😭

$CELC every time i leave a board, profits just disappear, fade, vanquish, poof, gone. Welcome me back Jabronis with loving arms if you want green dildo again. If you 👃 👃 👃 what the 📈 is 🧑‍🍳

$CELC Can’t believe it was less than a week ago that Chartistmind, who claimed to be right 7300 times, guaranteed that CELC was going down to $50. When I questioned his credibility, he blocked me, so I don’t know what he has posted since. Anyway….it’s comforting to see the recent price action.

$CELC 🏥 Celcuity presented updated Phase 3 VIKTORIA-1 results showing gedatolisib triplet and doublet achieved median PFS of 21.5 and 11.5 months versus 9.1 months for alpelisib plus fulvestrant, with ORR of 59% and 43% versus 33%, respectively, in HR+/HER2- advanced breast cancer patients without liver metastases. Market-relevant event

$CELC real world experience shows without fail: patients take the most efficacious option available within their safety limit. Not one takes an inferior drug out of better safety or convenience in this setting, and most patients live near treatment centers. Therefore this selling has little to do with "fundamentals". It's about being a massive loser that funds must cut due to mandates. Hopefully a few quarters of sales will change perception on the stock. I believe CELC is a $150 company today.

$CELC A few days now of holding up very well as rest of biotech gets sold off. Fingers crossed we have turned a corner here.

$CELC 🏥 Celcuity presented updated Phase 1b/2 data for gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer, with median rPFS of 15.7 months and rPFS6 of 82.2% after prior abiraterone and median rPFS of 9.1 months and rPFS6 of 62.5% after prior enzalutamide.

$CELC Celcuity announced this morning that four REVTORPYK/gedatolisib presentations have been accepted for ESMO 2026, including a late-breaking rapid oral presentation of additional subgroup analyses from the Phase 3 VIKTORIA-1 PIK3CA-mutant cohort. The abstracts will become public October 19, with presentations at ESMO in Madrid October 23–27. There are actually three areas worth watching:

$CELC a couple things: 1. This is a bad chart, and it's bad because commercials weren't up and running on day 1. 2. I've added more at the low 80s. CMC isn't hard for an IV small molecule, I'm not sure what tripped mgmt up here. This situation can be fixed with a proper launch and strong adoption. We shall see how it does going into EOY.

$CELC high chance to become the 1L aBC backbone as well in roughly 3 years. 1L is 2x larger than 2nd line. At 40% 2L penetration, CELC is a 7.5B enterprise value today. Would become 15B when 1st line reads out. And the PoS there is high. SubQ formulation will remove issue with IV injection. A BP with strong sales team can unlock more value with distribution, making the value of their purchase worth 20B relative to the 15B they paid. A 10B buyout today therefore makes a lot of sense, would easily clear BP hurdle rate.

$CELC October 19: ESMO clinical trial abstracts released. October 23: Prostate cancer Phase 1b/2 trial results presented. October 24: VIKTORIA-1 Phase 3 updated breast cancer data presented. October 24: VIKTORIA-2 Phase 3 first-line breast cancer trial presentation. November 2026 (expected): Q3 earnings and initial REVTORPYK commercial launch update. Date TBD: FDA acceptance and review timeline for PIK3CA-mutant indication. 2027 and beyond: VIKTORIA-2 Phase 3 results and potential expansion into first-line breast cancer treatment.

$CELC I’m going to hibernate for the winter. I have 3 pending sell orders. When I wake up on April 1st, 2027, I better be rich.

$CELC I’m just going to sit back and shut up. I couldn’t have been more wrong about this stock’s performance. I’m speechless. Still holding and hopeful.

$CELC A new FDA approved major cancer therapy and we are stair stepping back down to $50 zone again. Unbelievable and unforgivable.

$CELC Gedatolisib combo reaches 15.7-month rPFS in 22 prostate cancer patients after abiraterone. 📈 In the 22 men who had already taken abiraterone, FDA-approved breast cancer drugmaker Celcuity's combo posted median radiographic progression-free survival of 15.7 months, and 82.2% had not progressed at six months, as of an August 14, 2026 data cut-off 🏢 Prostate cancer would be a second market for a company worth about $3.21 billion at $65.57 a share at 16:00 ET on October 22, 2026, which held $754.0 million in cash and short-term investments on June 30, 2026 ⚠️ The case against is that results were weaker in the 18 men who had taken enzalutamide, at a 9.1-month median and a 62.5% six-month rate, and every group is small and uncontrolled across three doses 📅 Next: The randomized Phase 2 portion, which is meant to pick the Phase 3 dose, is expected to begin in the first half of 2027 Source: GlobeNewswire release, Oct 23

$CELC I have a feeling this is going to fly soon. Let's see where the price is in a month. (Not that my feelings have a great winning percentage...)

$CELC trading higher on speculation the documentary about CEO Brian Sullivan (Clayface) will perform better than expected on opening weekend

$CELC This October has not been kind to most of biotech.. Will November be the turnaround? I do believe so 🙏🏼 what do you guys think ?

$CELC it’s simple, look at the chart. Has 50 written all over it. Now if you have a mathematically advantageous system, can endure some temporary pain, you will make bank. 7300 10%+ 🚀 rippers and counting.

$CELC David Gryskas is the financial mastermind behind high-growth companies, helping turn ambitious businesses into billion-dollar acquisition targets. He’s been directly involved in deals and acquisitions worth more than $20 billion.